Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

PI-88 enters phase I in combination with Taxotere

Sep. 10, 2002

Kirin initiates phase II Mylovenge trials in Japan

Sep. 9, 2002

Enrollment completed in phase II study of EGF cancer vaccine

Sep. 6, 2002

Pfizer and Abgenix disclose monoclonal antibodies that specifically bind to IGF-IR

Sep. 3, 2002

Novuspharma and Micromet to codevelop MT-201 for cancer

Sep. 3, 2002

Enrollment under way for IL-13-PE38 in malignant glioma

Sep. 3, 2002

Beta-glucan and 3F8 exert synergistic antitumor effects in athymic mice with neuroblastoma

Sep. 2, 2002

Enhanced p53-specific T-cell immunity found in colorectal cancer patients treated with ALVAC-p53

Aug. 29, 2002

Aphton files for fast track designation for G17DT in gastric cancer

Aug. 27, 2002

Antisoma completes enrollment in phase I TheraFab trial

Aug. 26, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...